Neptune Medical Raises $97M, Launches Jupiter Endovascular

Neptune Medical recently received $97 million in Series D funding and launched a subsidiary, Jupiter Endovascular Inc., marking a strategic move to enhance its focus on gastrointestinal (GI) robotics while allowing Jupiter to advance in endovascular therapy. . Founder and CEO of Neptune, Alex TilsonHe emphasized that these developments will allow both companies to innovate within their fields.

Jupiter Endovascular construction follows Neptune’s recent appointment of Dr. Fred Moll, pioneer of surgical roboticsas the chairman of its board. Moll described the spinout as a strategic decision that will give Jupiter the resources and leadership needed to revolutionize endovascular therapy, while Neptune continues to focus on success in GI robotics.

Jupiter Endovascular has come out of stealth mode with $21 million in new funding and is developing its Endoportal Control platform. This technology aims to provide precise surgical access to catheter-based surgery, improving the stability and control needed in complex cardiac procedures. The company plans to use its new funding for important future research focused on pulmonary embolism, as well as expanding the clinical application of its technology.

Carl J. St. Bernard, who was recently appointed CEO of Jupiter Endovascularhighlighted the potential of Endoportal Control technology to revolutionize cardiovascular therapy by providing a minimally invasive yet highly controlled method of delivering therapies.

The Neptune and Jupiter funding rounds were supported by investors such as Sonder Capital and Olympus Corporation of the Americas. Sonder Capital Managing Partner, Kate Garrettnoted that Jupiter’s new approach may address important unmet clinical needs, particularly in the treatment of complex cardiovascular anatomies. Sonder Capital, founded by Moll, has a history of investing in health technology companies, including Intuitive Surgical and Auris Medical.

Use weather conditions

Endoportal Control technology from Jupiter Endovascular can have several impactful use cases:

• Treatment of Pulmonary Embolism: The technology can provide precise control over catheter-based procedures to remove blood clots from the lungs, reducing the risks associated with traditional surgery.
• Aortic Aneurysm Repair: By improving stability and accuracy, Endoportal Control can improve the accuracy of stent placement in the treatment of aortic aneurysms.
• Coronary Artery Disease: The technology could allow for more controlled and less invasive interventions in the treatment of blocked coronary arteries, potentially improving outcomes for patients with heart disease.
• Complex Cardiovascular Procedures: It can be used in challenging situations involving complex or hard-to-access cardiovascular structures, providing the precision needed to deliver treatment safely.
• Stroke Intervention: Endoportal administration may facilitate the removal of clots from cerebral arteries, improving the effectiveness of stroke interventions and reducing the risk of injury during the procedure.

These cases highlight the potential of Endoportal Control to revolutionize the way complex heart conditions are treated, making procedures safer and more efficient.

Filed Medical > Robotics. Read more about Medical & Robot.